HEALTHCNBC TOP
Eli Lilly takes weight-loss pill battle global with first Foundayo approval outside U.S.
Eli Lilly's drug, Foundayo, has won approval in the U.K., extending its participation in the weight-loss pill battle beyond the U.S. market. This development intensifies the competition between Eli Lilly and Novo Nordisk regarding their respective treatments.
Mentioned
Related Signal
Adjacent reporting
- Eli Lilly and Novo Nordisk raise profit outlook as weight-loss drug demand soars
- Eli Lilly is pushing its next-generation weight loss drug approval filing to early 2027
- Novo Nordisk is taking its new weight loss pill global
- Novo and Lilly are competing to win the GLP-1 pill market as they prepare for Medicare coverage
- People lost up to 85 pounds on Lilly’s experimental weight loss drug, company says
- The Wegovy pill is still dominating the GLP-1 pill market